MGMT-Unmethylated GlioblastomaPhase 2NCT05694416
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
A Phase 2 study testing Etoposide Plus Cisplatin in people with MGMT-Unmethylated Glioblastoma, run by Zhongnan Hospital.
Trial summary
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- MGMT-Unmethylated Glioblastoma
- What is being tested?
- Etoposide Plus Cisplatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2023to 1 Mar 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 70,
- performance status of 0-1 (Eastern Cooperative Oncology Group performance status),
- histologically confirmed MGMT gene promoter unmethylation glioblastoma
- no cerebrospinal fluid and distant metastatic disease.
- adequate hematologic, hepatic, and renal function
Who cannot join
- younger than 18 years;
- with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
Trial locations and contacts
No sites are listed yet.
Jianyin Huang, MD contact
About this study
Official title: Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
Read the detailed description
60 Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded.
60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups
- Conditions
- MGMT-Unmethylated Glioblastoma
- Being tested
- Etoposide Plus Cisplatin
- Keywords
- Etoposide Plus Cisplatin, Temozolomide, MGMT-Unmethylated Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Etoposide Plus CisplatinDrug
Also called EP
Etoposide Plus Cisplatin ivdrip d1-5
| Study group | Role | What they receive |
|---|---|---|
| Etoposide Plus Cisplatin group | Experimental | Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5 Receives: Drug: Etoposide Plus Cisplatin |
| Temozolomide group | No intervention | Temozolomide 150-200mg/m2 d1-5 |
What is being measured
The primary outcome is the main question the study is designed to answer.
OVER SURVIVAL
The length of time from the date of diagnosis to death from cancer
Measured: 2 YEARS
Secondary outcomes (1)
PFS
the length of time after primary treatment for glioblastoma ends that the patient survives without any progression of glioblastoma.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2023
- Study start1 Feb 2023 (estimated)
- Primary completion1 Mar 2024 (estimated)
- Study completion1 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MGMT-Unmethylated GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jianyin Huang, MD, Study chair, Wuhan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05694416
- Sponsor's protocol ID
- FUTURE
- Status last verified
- Jan 2023
- First submitted
- 12 Jan 2023
- Last updated
- 23 Jan 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
- ClinicalTrials.gov ID
- NCT05694416
- Acronym / sponsor ID
- FUTURE
- Conditions
- MGMT-Unmethylated Glioblastoma
- Keywords
- Etoposide Plus Cisplatin, Temozolomide, MGMT-Unmethylated Glioblastoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 1 Feb 2023 (estimated)
- Primary completion
- 1 Mar 2024 (estimated)
- Study completion
- 1 Mar 2025 (estimated)
- First posted
- 23 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
Detailed description
60 Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded.
60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Etoposide Plus Cisplatin group | Experimental | Drug: Etoposide Plus CisplatinEtoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5 |
| Temozolomide group | No intervention | –Temozolomide 150-200mg/m2 d1-5 |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age between 18 and 70,
- performance status of 0-1 (Eastern Cooperative Oncology Group performance status),
- histologically confirmed MGMT gene promoter unmethylation glioblastoma
- no cerebrospinal fluid and distant metastatic disease.
- adequate hematologic, hepatic, and renal function
Key exclusion criteria (2 listed)
- younger than 18 years;
- with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Etoposide Plus CisplatinAlso: EPEtoposide Plus Cisplatin ivdrip d1-5 | Drug | Etoposide Plus Cisplatin group |
Primary outcome
OVER SURVIVAL
Time frame: 2 YEARS
The length of time from the date of diagnosis to death from cancer
1 secondary outcome
PFS
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2023.
Related trials for MGMT-Unmethylated Glioblastoma
RecruitingPhase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
RecruitingPhase 2/3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
Not yet recruitingPhase 1
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
Not yet recruiting
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
RecruitingPhase 1/2
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Newly Diagnosed MGMT Unmethylated Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jianyin Huang, MD contact
Jianyin Huang, MD study chair
Wuhan University
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Etoposide Plus Cisplatin in people with MGMT-Unmethylated Glioblastoma, run by Zhongnan Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yahua Zhong, Phd (08602767813154, doctorzyh73@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OVER SURVIVAL (time frame: 2 YEARS). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2023.